First patients sought for groundbreaking gut cancer drug trial
NCT ID NCT07263594
Summary
This is the first-ever human study of an experimental drug called DB-1324 for people with advanced gastrointestinal cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose, see how the body processes the drug, and get an early look at whether it can shrink tumors. The study is for patients whose cancer has continued to grow despite standard treatments or for whom no standard treatment exists.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AUS01-0
Nedlands, Western Australia, 6009, Australia
-
AUS02-0
Randwick, New South Wales, 2031, Australia
-
AUS03-0
South Brisbane, Queensland, 4101, Australia
-
USA01-0
Huntersville, North Carolina, 28078, United States
-
USA02-0
Grand Rapids, Michigan, 49546, United States
-
USA03-0
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.